Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Strong evidence was found for both intra and intermolecular epitope spreading in patients with RNA polymerase III (POLR3) and the minor spliceosome specificities. PNAS, 11/07/2016. (Also see Antibodies)
Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma A new topical medicine, called SM04755, significantly decreased and even reversed fibrosis and inflammation in in vitro and in vivo mouse studies of scleroderma. American College of Rheumatology, 11/08/2016. (Also see Skin Fibrosis)
Lactose malabsorption in systemic sclerosis. Our findings highlight the fact that lactose breath test is a helpful, non–invasive method, by identifying the group of patients with systemic sclerosis with symptomatic lactose malabsorption that may benefit from a reduction in lactose intake. PubMed, Aliment Pharmacol Ther, 2016 Nov;44(10):1123-1133. (Also see Bowel Dysfunction)
Analysis of complement biomarkers in systemic sclerosis (SSc) indicates a distinct pattern in scleroderma renal crisis (SRC). We confirmed a significant decrease in complement haemolytic activity in SRC vs. non–SRC patients, indicating complement consumption, which indicates that complement activation is an important feature of SRC. PubMed, Arthritis Res Ther, 2016 Nov 18;18(1):267. (Also see Kidney (Renal) Involvement)
Intestinal dysbiosis is common in systemic sclerosis (SSc) and associated with gastrointestinal and extraintestinal features of disease. Intestinal dysbiosis was common in patients with SSc and was associated with gastrointestinal dysfunction, malnutrition and with some inflammatory, fibrotic and vascular extraintestinal features of SSc. PubMed, Arthritis Res Ther, 2016 Nov 29;18(1):278. (Also see Bowel Dysfunction)
Th–17 cytokines and interstitial lung involvement in systemic sclerosis (SSc). In diffuse SSc patients our results show a clear link between Th–17 cytokines measured both in exhaled breath condensate and in serum with interstitial lung involvement. PubMed, J Breath Re, 2016 Nov 21;10(4):046013. (Also see Cytokines and Pulmonary Fibrosis)
Pan peroxisome proliferator–activated receptors (PPAR) agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. These findings indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc. PubMed, Ann Rheum Dis, 2016 Dec;75(12):2175-2183. (Also see Skin Fibrosis)
Systemic sclerosis : What is currently available for treatment? Therapy options in systemic sclerosis have changed over the past 10 years and this trend will also continue in the future. PubMed, Internist (Berl), 2016 Dec;57(12):1155-1163. (Also see Scleroderma Clinical Trials)
Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy. Multiple studies have investigated the molecular basis of organ fibrosis and highlighted its multi–factorial genetic, epigenetic and environmental regulation. PubMed, J Cell Physiol, 11/24/2016. (Also see Causes of Scleroderma: Genetics)
Special considerations in pregnant systemic sclerosis (SSc) patients. Physiological changes arising during pregnancy may be the source of clinical problems in SSc women with organs with limited capacities. PubMed, Expert Rev Clin Immunol, 2016 Nov;12(11):1161-1173. (Also see Pregnancy and Systemic Scleroderma)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: